FN2 Earnings Intelligence
Edwards Lifesciences Corporation income statement (quarterly)
Edwards Lifesciences Corporation (EW) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $3,140.6 | $3,272.8 | $2,685.6 | $2,445.5 | $2,906.5 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $1,412.7 | $1,532.2 | $1,553.1 | $1,648.6 | $1,741 | $1,677.1 | $1,700.6 |
| % Growth | - | - | - | - | - | 8.0% | - |
| Gross Profit | $1,111.1 | $1,187.8 | $1,207.9 | $1,286 | $1,348.6 | - | - |
| % Margin | 78.7% | 77.5% | 77.8% | 78.0% | 77.5% | - | - |
| EBITDA | $431.4 | - | - | $518.5 | - | - | - |
| % Margin | 30.5% | - | - | 31.5% | - | - | - |
| Net Income | $358 | $333.2 | $291.1 | $380.7 | $241.9 | - | - |
| % Margin | 25.3% | 21.7% | 18.7% | 23.1% | 13.9% | - | - |
| Diluted EPS | $0.61 | $0.56 | $0.50 | $0.66 | $0.42 | $0.74 | $0.71 |
| % Growth | - | - | - | - | - | 47.7% | - |
| Operating Cash Flow | $280.4 | - | - | $43.8 | - | - | - |
| CapEx | $56 | - | - | $64.9 | - | - | - |
| Free Cash Flow | $224.4 | - | - | -$21.1 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $1,412.7 | $1,532.2 | $1,553.1 | $1,648.6 | $1,741 | $1,677.1 | $1,700.6 |
| Gross Profit | $1,111.1 | $1,187.8 | $1,207.9 | $1,286 | $1,348.6 | - | - |
| EBITDA | $431.4 | - | - | $518.5 | - | - | - |
| Net Income | $358 | $333.2 | $291.1 | $380.7 | $241.9 | - | - |
| Diluted EPS | $0.61 | $0.56 | $0.50 | $0.66 | $0.42 | $0.74 | $0.71 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3,140.6 | $3,272.8 | $2,685.6 | $2,445.5 | $2,906.5 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $597.8 | $598 | $598.2 | $598.5 | $598.7 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $280.4 | - | - | $43.8 | - |
| Capital Expenditure | $56 | - | - | $64.9 | - |
| Free Cash Flow | $224.4 | - | - | -$21.1 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 78.7% | 77.5% | 77.8% | 78.0% | 77.5% |
| EBITDA Margin | 30.5% | - | - | 31.5% | - |
| Net Margin | 25.3% | 21.7% | 18.7% | 23.1% | 13.9% |
| FCF Margin | 15.9% | - | - | -1.3% | - |
| Diluted EPS Growth | - | - | - | - | - |